Epoetin 4000

ApprovedSmall molecule

FFuture University in Egypt

Epoetin 4000 is one of 6 small molecule programs targeting Recurrent aphthous stomatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Aphthous StomatitisActive, not recruiting

Recurrent Aphthous StomatitisApproved

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Recurrent Aphthous Stomatitis

#DrugCompanyPhaseTrials

Kenalog

BBausch Health Americas, Inc.

Otezla

1 3

Epoetin 4000

FFuture University in Egypt

Approved

1 4

Omega 3

MMassachusetts General Hospital

Phase 2

1 5

Use Concentrated Growth Factor.

TTanta University

Phase 2

1 6

Trental

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Recurrent aphthous stomatitis1 trial

The Efficacy of Erythropoietin Oral Gel Versus Erythropoietin Mouthwash in the Management of Recurrent Aphthous Stomatitis

Completed·FFuture University in Egypt·Phase 4·NCT06923605·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Epoetin 4000. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Epoetin 4000 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Epoetin 4000. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Future University in Egypt company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFuture University in Egypt

Epoetin 4000

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Recurrent aphthous stomatitis1 trial

References

Drug Info

Quick Facts

Related News